SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
SUMMARY:
This is an open label study combining Rituxan and SDX-105. Rituxan will be given on day 1
followed by a 30-60 minute intravenous infusion of SDX-105 on day 2 and day 3. Treatment will
repeat every 21 days (a cycle). Treatment can continue for up to 6 cycles (about 4 months) if
tumor status improves and there are no unacceptable side effects. Patients will be followed
for up to 2 years or until disease progression.
RATIONALE:
Rituxan has been shown to increase the sensitivity of cells to chemotherapy. The combination
of SDX-105 and Rituxan has been effective in both the laboratory and in a recent clinical
study with Non-Hodgkin's lymphoma patients.
PURPOSE:
This study will evaluate the safety and effectiveness of SDX-105 plus Rituxan in patients
with Non-Hodgkin's lymphoma who have relapsed after taking Rituxan.